Nano Research · 2022 · 27 citations · 23 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCell-mediated ImmunityImmune Checkpoint RegulationT Cell BiologyT Cell Responses To TumorsPd-1 SignalingProgrammed Cell Death Protein 1 (Pd-1) PathwayT Cell-based Immunotherapy
Cancer cells aberrantly express immunosuppressive checkpoint ligands and produce certain metabolites that lead to T cell exhaustion. Immune checkpoint blockade (ICB) therapy that reinvigorates exhausted T cells have achieved impressive response in clinical cancer treatment. However, the limited clinical response rate and off-tumor toxicities restrict ICB therapy. Herein, cellular vesicles displaying anti-programmed cell death-1 (PD-1) single-chain variable fragment antibody (aPD-1-scFv) were prepared to reinvigorate T cell immunity to counteract cancer. The nanovesicles displaying aPD-1-scFv (aPD-1-scFv NVs) could enhance the anti-tumor activation of T cells through PD-1 blockade. Furthermore, NVs loading the A2a adenosine receptor (A2aR) antagonist CPI-444 assisted T cells to antagonize adenosine, an immunosuppressive metabolite produced by cancer cells. Hence, CPI-444 loaded aPD-1-scFv NVs could intensively increase the density and activity of tumor infiltrating T cells, directly restraining tumor progress and metastasis.
23
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Bin‐Zhi Qian, Jiufeng Li, Hui Zhang et al. · Nature · 2011 · 2.9K citations · Full text
Medicine, Cancer Biology, Oncology +14
Su Chul Jang, Oh Youn Kim, Chang Min Yoon et al. · ACS Nano · 2013 · 1K citations
Pharmacy, Oncology, Pharmacology +17
PD‐1 Blockade Cellular Vesicles for Cancer Immunotherapy
Xudong Zhang, Chao Wang, Jinqiang Wang et al. · Advanced Materials · 2018 · 294 citations
Medicine, Immunology, Oncology +17